Similar articles

• Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

  de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. de Bono JS, et al. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X. Lancet. 2010. PMID: 20888992 Clinical Trial.
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Petrylak DP, et al. N Engl J Med. 2004 Oct 7;351(15):1513-20. doi: 10.1056/NEJMoa041318. N Engl J Med. 2004. PMID: 15470214 Clinical Trial.
• Cabazitaxel for castration-resistant prostate cancer.

  Shigeta K, Miura Y, Naito Y, Takano T. Shigeta K, et al. Lancet. 2011 Jan 8;377(9760):121; author reply 122-3. doi: 10.1016/S0140-6736(11)60012-3. Lancet. 2011. PMID: 21215876 No abstract available.
• Future directions in the treatment of androgen-independent prostate cancer.

  Petrylak DP. Petrylak DP. Urology. 2005 Jun;65(6 Suppl):8-12. doi: 10.1016/j.urology.2005.04.020. Urology. 2005. PMID: 15939077 Review.
• Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.

  Van Poppel H. Van Poppel H. Can J Urol. 2005 Feb;12 Suppl 1:81-5. Can J Urol. 2005. PMID: 15780173 Review.